Peregrine issues patent covering vascular targeting agents

By Elaine Rigoli

Tampa, Fla., Sept. 26 - Peregrine Pharmaceuticals, Inc. announced the issuance of a U.S. patent covering broad therapeutic uses of its vascular targeting agent (VTA) technology platform in combination with standard treatments.

The Tustin, Calif., biotechnology company said it in-licensed worldwide exclusive rights to the technology, which includes the new patent, from UT Southwestern Medical Center.

Peregrine is collaborating with UT Southwestern researchers to evaluate VTA constructs in preclinical studies for solid tumor therapy. In addition to its own research efforts, Peregrine can sub-license rights under the VTA technology platform on an exclusive or non-exclusive basis, and it has already licensed rights for use of VTA technology to a number of other companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.